Ben Venue Laboratories, Inc. Awarded
National Cancer Institute Contract
BEDFORD, OH—March 3, 2003—Ben Venue Laboratories, Inc.
has again been awarded a five year contract with the National
Cancer Institute (NCI) to develop and manufacture investigational
compounds that will be studied in a variety of tumor types.
This award is one of an uninterrupted series of contracts
that have been in place at Ben Venue since the late 1960’s,
and is one of the longest running in NCI history. The amount
of the award is $8 million and the term of the contract
is from March
3, 2003 through February 29, 2008.
Ben Venue's NCI contract supports process development/scale-up,
specialized process and analytical method development/validation
as well as manufacturing of investigational anti-tumor
agents. The NCI issued requests for proposals at two levels
of effort, and BVL bid on
and was awarded both.
"Ben Venue is very proud to have been awarded this contract," said
Thomas Russillo, President and COO. "It gives us the opportunity
to assist in making promising new research therapies available
for cancer patients. Through our contracts in the past,
we have participated in the development of many of the
leading oncologic agents used today, including methotrexate,
daunorubicin, paclitaxel, cisplatin, BiCNU, dacarbazine
(DTIC), Fludara and calcium leucovorin."
The Boehringer Ingelheim group of companies ranks among
the 20 leading pharmaceutical corporations in the world
and has 156 affiliated companies in 44 countries worldwide.
Focusing on human pharmaceuticals and animal health, it
posted revenues of $7.2 billion in 2002.
Since 1885, Boehringer Ingelheim has been a privately-held
company with a long history of successfully marketed pharmaceutical
innovations. Research and development, production and distribution
facilities are located around the globe. In 2002, Boehringer
Ingelheim’s R&D spending was more than $1.2 billion U.S.
which is about a fifth of net sales in Prescription Medicines.
For more information on Boehringer Ingelheim, please see
the international Internet website www.boehringer-ingelheim.com. |
